Thus, several CAR-T cell medicines, such as CD19-targeted Tisagenlecleucel (Kymriah®), Axicabtagene ciloleucel (Yescarta®), brexucabtagene autoleucel (Tecartus®), lisocabtagene maraleucel (Breyanzi®), B cell maturation antigen (BCMA)-targeted idecabtagene vicleucel (Abecma®), and ciltacabtagene autoleucel (Carvykti®), have been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of hematological malignancies, including lymphomas, some forms of leukemia, and most recently for the treatment of multiple myeloma (MM) (11–14, 40, 41). This evidence concerns the gene CD19 and lymphoma.